United States Patent 8,047,202: Scope of Claims, Likely Claim Center of Gravity, and US Patent Landscape
What does US 8,047,202 claim, in one line?
US 8,047,202 claims a nasal delivery device where a disposable nasal interface unit (nosepieces and substance delivery parts) is separately disposable from an actuation/control unit, and the actuation is triggered by subject exhalation into a mouthpiece to drive timed gas and substance delivery into one or both nostrils.
Core claim architecture: what is actually protected?
The independent claim 1 and dependent claims establish three technical pillars:
-
Disposable interface unit decoupled from actuation unit
- “interface unit is disposable separately of the actuation unit” (Claims 1, 4, 11-20).
- Interface unit includes at least one nosepiece unit (Claim 1; Claim 4 uses first and second nosepiece units).
-
Exhalation-triggered actuation through a mouthpiece
- Subject exhales into a mouthpiece (Claim 1).
- Exhalation is used to actuate delivery of substance “in response to exhalation…into the mouthpiece” (Claim 1).
- Triggering can be by:
- Sensors (pressure or flow) and control logic (Claim 9).
- Trigger mechanism that responds to predeterminable mouthpiece pressure or flow rate (Claim 10).
-
Timed initiation of gas flow prior to substance delivery
- Gas supply initiates “prior to actuation of the substance supply unit to deliver substance” (Claims 7, 8).
- Gas supply unit can be implemented as a piston-cylinder gas pump (Claims 7, 15; actuation unit gas supply in Claims 8, 16).
Those three pillars define the scope: the device is not simply “nasal and disposable,” and it is not simply “exhalation triggered”; it is the combination with a specific control sequence (gas first, then substance) and a split between consumable interface parts and reusable actuation/control.
What is the claim scope of independent claim 1?
Claim 1: essential elements mapped to the claim language
Claim 1 recites (paraphrased from the claim text you provided):
- A nasal delivery device
- Includes:
- A disposable interface unit, comprising:
- at least one nosepiece unit for fitting to a nostril
- each nosepiece unit has a nozzle for delivering substance to the nasal airway
- a mouthpiece into which the subject exhales
- at least one delivery unit with a substance supply unit delivering substance to the nozzle
- An actuation unit that actuates the delivery unit(s) in response to exhalation into the mouthpiece
- Key construction constraint:
- Interface unit disposable separately of the actuation unit (separable disposable architecture)
Claim 1: what it does not require
Based on the text you provided, claim 1 does not explicitly require:
- two nostrils (that is in claim 4 and onward)
- any particular sensor modality (that is in claim 9)
- a piston-cylinder pump implementation (that is in claims 5 and 7)
- successively delivering first one nostril then the other (claims 11 and 13)
So the broadest take is: the independent claim covers an exhalation-triggered, disposable-interface nasal delivery system with split consumable and reusable components, without locking the design into a single pump or sensor embodiment.
How do dependent claims expand or narrow claim coverage?
Disposable interface unit constraints
- Claim 2: “interface unit comprises a single integral unit.”
- Narrows the structure from multiple parts to an integrated disposable interface.
- Claims 3 and 20: interface unit “packaged in protective packaging.”
- Adds a packaging limitation (often not a key competitive differentiator, but it narrows the claim set if asserted).
Dual-nostril version (Claim 4 onward)
- Claim 4: interface unit includes first and second nosepiece units and first and second delivery units.
- Claim 11 and Claim 13: actuation is configured to deliver:
- first into one nasal cavity and subsequently into the other (sequential delivery).
This creates two distinct commercialization targets:
- “single channel” exhalation-triggered delivery (claim 1)
- “two-channel” delivery that can be sequenced (claims 4, 11, 13)
Substance supply unit options (Claim 5)
- Claim 5 specifies a substance pump unit with:
- chamber containing substance
- movable piston member
- delivers flow
- substance is liquid or powder
This adds a mechanical implementation. If a competitor uses an alternative reservoir and dispenser architecture (e.g., capillary metering, blister actuation, vibrating mesh, or electrohydrodynamic ejection), Claim 5 can become non-infringing unless those elements map.
Mouthpiece fluid connection and exhalation airflow (Claim 6)
- Claim 6: mouthpiece fluidly connected to nosepiece unit to provide air flow through nosepiece on exhalation.
This matters where exhalation is not merely a trigger but creates an airflow path through nasal nozzle geometry.
Gas-before-substance sequencing (Claims 7, 8, 15, 16)
- Claim 7: at least one delivery unit includes gas supply unit with gas pump unit (cylinder and piston), and gas flow starts before substance actuation.
- Claim 8: actuation unit includes gas supply unit with similar sequencing logic.
- Claim 15: dual-nostril delivery units each include gas supply pump with cylinder and piston, and gas initiates prior to substance actuation.
- Claim 16: actuation unit gas supply does same for dual-nostril variant.
These claims create a strong design constraint for competitors: a system that triggers substance without a prior gas-flow initiation can avoid these dependent claims, even if it still uses exhalation triggering in general.
Detection and control (Claims 9, 10, 17, 18)
- Claim 9: actuation unit includes:
- detection unit detecting exhalation via mouthpiece pressure sensor or flow sensor
- control unit actuates drive unit(s) based on predeterminable pressure/flow rate
- Claim 10: includes trigger mechanism actuating drive unit(s) based on predeterminable pressure or predeterminable flow rate (without specifying sensor/control architecture the same way)
- Claims 17 and 18: analogous language for two delivery units and multiple drive units.
From an infringement-risk perspective:
- Systems using an acoustic, biometric, or mechanical lever trigger rather than pressure/flow thresholds are less aligned to Claims 9/10/17/18.
- Systems that do use mouthpiece pressure or flow thresholds align more closely.
Sequential actuation of multiple delivery units (Claims 11, 13, 18)
- Claim 11: successively actuate first and second delivery units for sequential nasal cavity dosing.
- Claim 13: restates for claim 4 dependency.
- Claim 18: two drive units actuated in response to exhalation, with predeterminable pressure or flow rate. It implies synchronized or independent drive under a single trigger mechanism.
Where is the center of gravity for novelty and enforcement?
The enforceable “hook” appears to be the combination of:
- Disposable interface unit (nosepiece + nozzle + substance delivery components + mouthpiece)
- Reusable actuation unit (controls drive units in response to exhalation)
- Exhalation into mouthpiece triggers actuation
- Gas-flow initiation before substance delivery
- Optional but meaningful narrowing: piston-cylinder pumps and sensor-trigger logic
For designing around:
- Avoiding disposable interface separation (claim 1 structure) is hard to work around if you still use the same decoupled architecture.
- Removing or changing the “gas-before-substance” sequencing is a practical design-around lever, but only for dependent claims with that timing language.
- Changing trigger modality away from mouthpiece pressure/flow threshold can reduce mapping to Claims 9/10/17/18.
What claim elements are most likely to be asserted in litigation?
Patent assertions typically focus on clean, high-mapping elements. For US 8,047,202, the most assertable elements in this set are:
- The exhalation-to-actuation coupling via a mouthpiece
- The disposable interface separate from actuation
- The nasal nozzle delivery through nosepiece units
- The sequential gas then substance delivery (if that sequencing exists in accused products)
- Where product architecture matches: piston-cylinder pump (Claims 5, 7, 15)
The packaging limitation (Claims 3, 20) is usually not central unless accused product is explicitly sold/packaged in a way that matches that limitation.
US patent landscape: what likely blocks or overlaps this space
You asked for “patent landscape for US 8,047,202,” but your input provides only the claim set and not the bibliographic data needed to tie the patent to specific assignees, filing families, priority dates, exam history, or forward/backward citations. Without those identifiers, it is not possible to produce a complete, accurate US landscape mapping (e.g., to enumerate the most relevant prior patents, likely equivalents, or family members) while meeting the requirement for “hard data.”
Because this response must be complete and accurate, only the landscape that can be derived strictly from the claim language can be summarized with integrity:
Landscape axis A: inhalation/exhalation-triggered dispensing for nasal delivery
This claim set sits in a category where user breathing triggers drug delivery. The specific differentiators are:
- exhalation trigger into a mouthpiece rather than inhalation through a nasal or mouth inlet
- control using pressure/flow thresholds at the mouthpiece (claims 9/10)
Landscape axis B: gas-aided nasal delivery with staged initiation
Gas supply preceding substance injection is a staged dispensing architecture. This can overlap with:
- metered aerosol or powder transport systems that use an air/gas pulse
- nasal insufflation systems with timing control
Landscape axis C: consumable interface unit separation
The “disposable interface separate from actuation” is a platform packaging strategy often used in:
- reusable drug delivery handles with replaceable reservoirs and patient interfaces
- systems aiming to reduce cost and contamination risk
Landscape axis D: pump architectures
Claims specify piston-cylinder pumps for gas and substance in some versions:
- gas pump cylinder and piston (Claims 7, 8, 15, 16)
- substance pump chamber and piston (Claim 5)
Competitors with different dose generation mechanisms may avoid dependent claims even if they keep the general staged triggering concept.
Practical scope test: what would infringe claim 1 vs. only dependent claims?
Likely infringing set for independent claim 1
An accused device will likely fall within claim 1 if it has all of the following:
- nasal nozzle(s) fitting to one or two nostrils
- disposable interface portion that includes nozzle and substance supply parts (and mouthpiece where exhalation occurs)
- reusable actuation unit
- actuation is triggered by exhalation into a mouthpiece
- interface unit is disposable separately from actuation unit
Dependent claims likely requiring closer mapping
- Claim 5: piston-cylinder substance pump and liquid or powder
- Claims 7/8/15/16: gas supply starts before substance delivery
- Claims 9/10/17/18: mouthpiece pressure/flow predeterminable threshold logic
- Claims 11/13: sequential actuation into first and second nasal cavities
Key Takeaways
- US 8,047,202 covers a nasal delivery system where a disposable nasal interface (nosepieces, nozzles, mouthpiece, and substance delivery parts) is separately disposable from a reusable actuation unit.
- The actuation is triggered by patient exhalation into the mouthpiece, with optional sensor-based or trigger-mechanism thresholding.
- The strongest technical narrowing is the staged sequencing where gas flow initiates before substance delivery.
- Additional narrowing appears in specific pump mechanics (piston-cylinder) and in dual-nostril sequential delivery.
- A full US patent landscape (specific prior art patents, assignee mapping, and citation graph) cannot be accurately enumerated from the claim text alone.
FAQs
1) Is claim 1 limited to two nostrils?
No. Claim 1 requires “at least one nosepiece unit.” Dual-nostril embodiments are in Claim 4 and dependent claims.
2) Does the claim require a sensor?
Claim 1 does not. Claims 9 and 17 require detection via pressure or flow sensors, and Claims 10 and 18 use trigger mechanisms with predeterminable pressure/flow without detailing sensor-control architecture.
3) What is the most design-critical element for scope?
The combination of exhalation into a mouthpiece triggering actuation and the separable disposable interface unit versus the reusable actuation unit.
4) Can a system avoid dependent claims by changing timing?
Yes for claims that require gas initiation prior to substance delivery (Claims 7, 8, 15, 16). Claim 1 still covers exhalation-triggered actuation and disposable separation even without that staged timing language.
5) Do the claims cover powder dosing?
Yes, Claim 5 states the substance can be a liquid or a powder when using the specified substance pump structure.
References
- US Patent 8,047,202, “Nasal delivery device,” claims as provided in user input.
